UroGen Pharma to Present at Upcoming Investor ConferencesGlobeNewswireAugust 21, 2025PRINCETON, N.J., Aug. 21, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will participate in the following investor conferences in September.
Wells Fargo Healthcare Conference
Date / Time:September 3rd, at 2:15 PM ETFormat:Fireside ChatLocation:Boston, MACantor Fitzgerald Global Healthcare Conference
Date / Time:September 4th, at 3:55 PM ETFormat:Fireside ChatLocation:New York, NYH.C. Wainwright 27th Annual Global Healthcare Conference
Date / Time:September 8th, at 9:00 AM ETFormat:Fireside ChatLocation:New York, NYThe conference webcasts will be available through the Events section of the Company's Investor Relations website. Replays will be available for approximately 90 days following the event.
About UroGen Pharma Ltd.
UroGen is a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers because patients deserve better options. UroGen has developed RTGel(R) reverse-thermal hydrogel, a proprietary sustained-release, hydrogel-based platform technology that has the potential to improve the therapeutic profiles of existing drugs. UroGen's sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. Our first product is approved to treat low-grade upper tract urothelial cancer, and our second product is the first and only FDA-approved medication for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer. Both medicines are designed to ablate tumors by non-surgical means. UroGen is headquartered in Princeton, NJ with operations in Israel. Visit www.urogen.com to learn more or follow us on X (Twitter), @UroGenPharma.
INVESTORS:
Vincent PerroneSenior Director, Investor Relationsvincent.perrone@urogen.com609-460-3588 ext. 1093
MEDIA:
Cindy RomanoDirector, Corporate Communicationscindy.romano@urogen.com609-460-3583 ext. 1083
COMTEX_468201568/2010/2025-08-21T08:00:01
PRINCETON, N.J., Aug. 21, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will participate in the following investor conferences in September.
Wells Fargo Healthcare Conference
Date / Time:September 3rd, at 2:15 PM ETFormat:Fireside ChatLocation:Boston, MACantor Fitzgerald Global Healthcare Conference
Date / Time:September 4th, at 3:55 PM ETFormat:Fireside ChatLocation:New York, NYH.C. Wainwright 27th Annual Global Healthcare Conference
Date / Time:September 8th, at 9:00 AM ETFormat:Fireside ChatLocation:New York, NYThe conference webcasts will be available through the Events section of the Company's Investor Relations website. Replays will be available for approximately 90 days following the event.
About UroGen Pharma Ltd.
UroGen is a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers because patients deserve better options. UroGen has developed RTGel(R) reverse-thermal hydrogel, a proprietary sustained-release, hydrogel-based platform technology that has the potential to improve the therapeutic profiles of existing drugs. UroGen's sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. Our first product is approved to treat low-grade upper tract urothelial cancer, and our second product is the first and only FDA-approved medication for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer. Both medicines are designed to ablate tumors by non-surgical means. UroGen is headquartered in Princeton, NJ with operations in Israel. Visit www.urogen.com to learn more or follow us on X (Twitter), @UroGenPharma.
INVESTORS:
Vincent PerroneSenior Director, Investor Relationsvincent.perrone@urogen.com609-460-3588 ext. 1093
MEDIA:
Cindy RomanoDirector, Corporate Communicationscindy.romano@urogen.com609-460-3583 ext. 1083
COMTEX_468201568/2010/2025-08-21T08:00:01
21.91% $4.23
